Eduardo Arellano‐Rodrigo

2.9k total citations
49 papers, 1.7k citations indexed

About

Eduardo Arellano‐Rodrigo is a scholar working on Genetics, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Eduardo Arellano‐Rodrigo has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 26 papers in Hematology and 19 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eduardo Arellano‐Rodrigo's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Eosinophilic Disorders and Syndromes (13 papers). Eduardo Arellano‐Rodrigo is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Eosinophilic Disorders and Syndromes (13 papers). Eduardo Arellano‐Rodrigo collaborates with scholars based in Spain, United States and Germany. Eduardo Arellano‐Rodrigo's co-authors include Francisco Cervantes, Alberto Álvarez‐Larrán, Joan Carles Reverter, Dolors Colomer, Neus Villamor, Beatríz Bellosillo, Juan Carlos Hernández‐Boluda, Emili Montserrat, A Domingo and Arturo Pereira and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Eduardo Arellano‐Rodrigo

49 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eduardo Arellano‐Rodrigo Spain	20	1.3k	839	715	595	270	49	1.7k
Maria Luigia Randi Italy	26	1.9k 1.5×	1.6k 1.9×	1.0k 1.4×	801 1.3×	123 0.5×	109	2.6k
Olle Linder Sweden	15	675 0.5×	1.4k 1.6×	595 0.8×	171 0.3×	320 1.2×	35	1.8k
Dong-Wook Kim South Korea	18	635 0.5×	938 1.1×	89 0.1×	424 0.7×	53 0.2×	84	1.3k
A. M. Cumming United Kingdom	18	362 0.3×	1.6k 1.9×	80 0.1×	59 0.1×	390 1.4×	36	1.8k
Ivo Elezović Serbia	17	153 0.1×	667 0.8×	199 0.3×	46 0.1×	101 0.4×	78	917
Steven Andrèsen United States	16	138 0.1×	417 0.5×	211 0.3×	66 0.1×	40 0.1×	48	915
Darko Antić Serbia	14	203 0.2×	297 0.4×	115 0.2×	21 0.0×	151 0.6×	96	823
Ming‐Chung Kuo Taiwan	20	361 0.3×	686 0.8×	379 0.5×	46 0.1×	18 0.1×	84	1.2k
Moon Ju Jang South Korea	17	63 0.0×	149 0.2×	323 0.5×	88 0.1×	195 0.7×	40	962
Krystyna Zawilska Poland	14	151 0.1×	537 0.6×	87 0.1×	32 0.1×	412 1.5×	90	1.2k

Countries citing papers authored by Eduardo Arellano‐Rodrigo

Since Specialization

Citations

This map shows the geographic impact of Eduardo Arellano‐Rodrigo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Arellano‐Rodrigo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Arellano‐Rodrigo more than expected).

Fields of papers citing papers by Eduardo Arellano‐Rodrigo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Arellano‐Rodrigo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Arellano‐Rodrigo. The network helps show where Eduardo Arellano‐Rodrigo may publish in the future.

Co-authorship network of co-authors of Eduardo Arellano‐Rodrigo

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Arellano‐Rodrigo. A scholar is included among the top collaborators of Eduardo Arellano‐Rodrigo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Arellano‐Rodrigo. Eduardo Arellano‐Rodrigo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

López‐Guerra, Mònica, Juan Carlos García‐Pagán, Eduardo Arellano‐Rodrigo, et al.. (2024). Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Annals of Hematology. 103(3). 737–747. 1 indexed citations

Escolar, Ginés, Maribel Díaz‐Ricart, & Eduardo Arellano‐Rodrigo. (2017). Andexanet alpha: A recombinant mimetic of human factor Xa for thereversal of anticoagulant therapies. Drugs of today. 53(5). 271–271. 4 indexed citations

Escolar, Ginés, Maribel Díaz‐Ricart, & Eduardo Arellano‐Rodrigo. (2017). Betrixaban: a direct oral inhibitor of activated factor X for theprophylaxis of venous thromboembolism in patients hospitalized foracute medical illness. Drugs of today. 53(8). 423–423. 1 indexed citations

Escolar, Ginés, Maribel Díaz‐Ricart, Eduardo Arellano‐Rodrigo, & Ana M. Galán. (2014). The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Metabolism & Toxicology. 10(3). 445–458. 4 indexed citations

Escolar, Ginés, Eduardo Arellano‐Rodrigo, Jaume Roquer, et al.. (2013). Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PLoS ONE. 8(11). e78696–e78696. 111 indexed citations

Hernández‐Boluda, Juan Carlos, Arturo Pereira, Francisco Cervantes, et al.. (2013). Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Annals of Hematology. 92(6). 771–775. 25 indexed citations

Arellano‐Rodrigo, Eduardo, et al.. (2011). Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 23(5). 336–343. 12 indexed citations

Álvarez‐Larrán, Alberto, Francisco Cervantes, Arturo Pereira, et al.. (2010). Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 116(8). 1205–1210. 164 indexed citations

Martínez‐Trillos, Alejandra, Anna Gayà, Margherita Maffioli, et al.. (2010). Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Annals of Hematology. 89(12). 1233–1237. 108 indexed citations

10.

Casellas, M., et al.. (2010). Inherited antithrombin deficiency and pregnancy: Maternal and fetal outcomes. European Journal of Obstetrics & Gynecology and Reproductive Biology. 149(1). 47–51. 37 indexed citations

11.

Arellano‐Rodrigo, Eduardo, Alberto Álvarez‐Larrán, Joan Carles Reverter, et al.. (2008). Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. American Journal of Hematology. 84(2). 102–108. 106 indexed citations

12.

Rivas‐Gándara, Nuria, Ignacio Ferreira‐González, Pilar Tornos, et al.. (2007). Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart. 94(2). 205–210. 16 indexed citations

13.

Álvarez‐Larrán, Alberto, Eduardo Arellano‐Rodrigo, Joan Carles Reverter, et al.. (2007). Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Annals of Hematology. 87(4). 269–276. 47 indexed citations

14.

Muntañola, Ana, Francesc Bosch, Pedro Arguis, et al.. (2007). Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 25(12). 1576–1580. 31 indexed citations

15.

Álvarez‐Larrán, Alberto, Francisco Cervantes, Beatríz Bellosillo, et al.. (2007). Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 21(6). 1218–1223. 93 indexed citations

16.

Álvarez‐Larrán, Alberto, Francisco Cervantes, Beatríz Bellosillo, et al.. (2006). Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. Blood. 108(11). 3598–3598. 5 indexed citations

17.

Cervantes, Francisco, Alberto Álvarez‐Larrán, Eduardo Arellano‐Rodrigo, et al.. (2005). Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 20(1). 55–60. 58 indexed citations

18.

Cervantes, Francisco, Alberto Álvarez‐Larrán, A Domingo, Eduardo Arellano‐Rodrigo, & Emili Montserrat. (2005). Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients. British Journal of Haematology. 129(6). 771–775. 95 indexed citations

19.

Arellano‐Rodrigo, Eduardo, et al.. (2003). Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis. Annals of Hematology. 83(1). 67–70. 25 indexed citations

20.

Camós, Mireia, Eduardo Arellano‐Rodrigo, Ana Muntañola, et al.. (2003). Idiopathic Myelofibrosis Associated with Classic Polyarteritis Nodosa. Leukemia & lymphoma. 44(3). 539–541. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact